Current applications of STAT3 inhibitors in cancer therapy indicate that small-molecule inhibitors often have several drawbacks, including poor selectivity and specificity, inadequate cellular permeability, low bioavailability, and off-target effects. This evidence concerns the gene STAT3 and cancer.